{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:35:47Z","timestamp":1791254147841,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T00:00:00Z","timestamp":1634688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T00:00:00Z","timestamp":1634688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["220171\/Z\/20\/Z"],"award-info":[{"award-number":["220171\/Z\/20\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Persistent hepatitis C virus (HCV) infection is a major cause of chronic liver disease, worldwide. With the development of direct-acting antivirals, treatment of chronically infected patients has become highly effective, although a subset of patients responds less well to therapy. Sofosbuvir is a common component of current de novo or salvage combination therapies, that targets the HCV NS5B polymerase. We use pre-treatment whole-genome sequences of HCV from 507 patients infected with HCV subtype 3a and treated with sofosbuvir containing regimens to detect viral polymorphisms associated with response to treatment. We find three common polymorphisms in non-targeted HCV NS2 and NS3 proteins are associated with reduced treatment response. These polymorphisms are enriched in post-treatment HCV sequences of patients unresponsive to treatment. They are also associated with lower reductions in viral load in the first week of therapy. Using in vitro short-term dose-response assays, these polymorphisms do not cause any reduction in sofosbuvir potency, suggesting an indirect mechanism of action in decreasing sofosbuvir efficacy. The identification of polymorphisms in NS2 and NS3 proteins associated with poor treatment outcomes emphasises the value of systematic genome-wide analyses of viruses in uncovering clinically relevant polymorphisms that impact treatment.<\/jats:p>","DOI":"10.1038\/s41467-021-25649-6","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T09:30:18Z","timestamp":1634722218000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7778-7137","authenticated-orcid":false,"given":"David A.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlota","family":"Fernandez-Antunez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Magri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8596-0366","authenticated-orcid":false,"given":"Rory","family":"Bowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimisha","family":"Chaturvedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8240-939X","authenticated-orcid":false,"given":"Jacques","family":"Fellay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"McLauchlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham R.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William L.","family":"Irving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"STOP-HCV Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Brainard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Burgess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Cooke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Gore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Guha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Halford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cham","family":"Herath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Howe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Hudson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Irving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Khakoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Klenerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Koletzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Massetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamyo","family":"Mbisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"McHutchison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"McKeating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alec","family":"Miners","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris C. A.","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Targett-Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Vickerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Zitzmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Simmonds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Pedergnana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santseharay","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7815-4806","authenticated-orcid":false,"given":"Jens","family":"Bukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0860-0831","authenticated-orcid":false,"given":"Eleanor","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2790-8353","authenticated-orcid":false,"given":"M. Azim","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,20]]},"reference":[{"key":"25649_CR1","unstructured":"World Health Organization. Global Hepatitis Report, 2017. (World Health Organization, 2017)."},{"key":"25649_CR2","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","volume":"373","author":"JJ Feld","year":"2015","unstructured":"Feld, J. J. et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 Infection. N. Engl. J. Med. 373, 2599\u20132607 (2015).","journal-title":"N. Engl. J. Med."},{"key":"25649_CR3","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/hep.29541","volume":"67","author":"D Wyles","year":"2017","unstructured":"Wyles, D. et al. Glecaprevir\/pibrentasvir for HCV genotype 3 Patients with cirrhosis and\/or prior treatment experience: a partially randomized phase III clinical trial. Hepatology 67, 514\u2013523 (2017).","journal-title":"Hepatology"},{"key":"25649_CR4","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1128\/AAC.00399-10","volume":"54","author":"C Niu","year":"2010","unstructured":"Niu, C. et al. PSI-7851, a pronucleotide of -D-2\u2032-deoxy-2\u2032-fluoro-2\u2032-c-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. Antimicrob. Agents Chemother. 54, 3187\u20133196 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"25649_CR5","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","volume":"370","author":"S Zeuzem","year":"2014","unstructured":"Zeuzem, S. et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N. Engl. J. Med. 370, 1993\u20132001 (2014).","journal-title":"N. Engl. J. Med."},{"key":"25649_CR6","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","volume":"69","author":"JM Pawlotsky","year":"2018","unstructured":"Pawlotsky, J. M. et al. EASL recommendations on treatment of hepatitis C 2018. J. Hepatol. 69, 461\u2013511 (2018).","journal-title":"J. Hepatol."},{"key":"25649_CR7","unstructured":"American Association for the Study of Liver Diseases. Recommendations for Testing, Managing, and Treating Hepatitis C | HCV Guidance. (American Association for the Study of Liver Diseases) http:\/\/www.hcvguidelines.org\/ (2020)."},{"key":"25649_CR8","doi-asserted-by":"crossref","unstructured":"Svarovskaia, E. S. et al. Infrequent development of resistance in genotype 1-6 hepatitis c virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin. Infect. Dis. 59, 1666\u20131674 (2014).","DOI":"10.1093\/cid\/ciu697"},{"key":"25649_CR9","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/hep.30225","volume":"69","author":"S Fourati","year":"2019","unstructured":"Fourati, S. et al. Frequent antiviral treatment failures in patients infected with hepatitis C virus genotype 4, subtype 4r. Hepatology 69, 513\u2013523 (2019).","journal-title":"Hepatology"},{"key":"25649_CR10","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.jhep.2017.06.035","volume":"67","author":"A da Silva Filipe","year":"2017","unstructured":"da Silva Filipe, A. et al. Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries. J. Hepatol. 67, 1348\u20131350 (2017).","journal-title":"J. Hepatol."},{"key":"25649_CR11","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1002\/hep.29837","volume":"69","author":"D Smith","year":"2019","unstructured":"Smith, D. et al. Resistance analysis of genotype 3 HCV indicates subtypes inherently resistant to NS5A inhibitors. Hepatology 69, 1861\u20131872 (2019).","journal-title":"Hepatology"},{"key":"25649_CR12","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S2468-1253(18)30343-1","volume":"4","author":"L Wei","year":"2019","unstructured":"Wei, L. et al. Sofosbuvir\u2013velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial. Lancet Gastroenterol. Hepatol. 4, 127\u2013134 (2019).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"25649_CR13","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.jhep.2017.03.014","volume":"67","author":"TM Welzel","year":"2017","unstructured":"Welzel, T. M. et al. Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses. J. Hepatol. 67, 224\u2013236 (2017).","journal-title":"J. Hepatol."},{"key":"25649_CR14","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1093\/infdis\/jiv564","volume":"213","author":"ES Svarovskaia","year":"2016","unstructured":"Svarovskaia, E. S. et al. L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions. J. Infect. Dis. 213, 1240 (2016).","journal-title":"J. Infect. Dis."},{"key":"25649_CR15","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/hep4.1060","volume":"1","author":"EJ Gane","year":"2017","unstructured":"Gane, E. J. et al. The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatment. Hepatol. Commun. 1, 538\u2013549 (2017).","journal-title":"Hepatol. Commun."},{"key":"25649_CR16","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1053\/j.gastro.2017.11.007","volume":"154","author":"J Dietz","year":"2018","unstructured":"Dietz, J. et al. Patterns of resistance-associated substitutions in patients with chronic HCV infection following treatment with direct-acting antivirals. Gastroenterology 154, 976\u2013988.e4 (2018).","journal-title":"Gastroenterology"},{"key":"25649_CR17","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1053\/j.gastro.2019.05.007","volume":"157","author":"PAC Wing","year":"2019","unstructured":"Wing, P. A. C. et al. Amino acid substitutions in genotype 3a hepatitis C virus polymerase protein affect responses to sofosbuvir. Gastroenterology 157, 692\u2013704.E9 (2019).","journal-title":"Gastroenterology"},{"key":"25649_CR18","doi-asserted-by":"crossref","unstructured":"Mejer, N. et al. Mutations identified in the hepatitis C virus (HCV) polymerase of patients with chronic HCV treated with ribavirin cause resistance and affect viral replication fidelity. Antimicrob. Agent. Chemother. 64, e01417\u201320 (2020).","DOI":"10.1128\/AAC.01417-20"},{"key":"25649_CR19","doi-asserted-by":"crossref","unstructured":"Bamford, C. G. G. & McLauchlan, J. An interferon lambda 4-associated variant in the hepatitis C virus RNA polymerase affects viral replication in infected cells. J. Gen. Virol. 102, 001495 (2021).","DOI":"10.1099\/jgv.0.001495"},{"key":"25649_CR20","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1053\/j.gastro.2015.07.043","volume":"149","author":"GR Foster","year":"2015","unstructured":"Foster, G. R. et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology 149, 1462\u20131470 (2015).","journal-title":"Gastroenterology"},{"key":"25649_CR21","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/ng.3835","volume":"49","author":"MA Ansari","year":"2017","unstructured":"Ansari, M. A. et al. Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus. Nat. Genet. 49, 666\u2013673 (2017).","journal-title":"Nat. Genet."},{"key":"25649_CR22","doi-asserted-by":"crossref","unstructured":"Tong, X. et al. In vivo emergence of a novel mutant L159F\/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir. J. Infect. Dis. 209, 668\u2013675 (2014).","DOI":"10.1093\/infdis\/jit562"},{"key":"25649_CR23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1534\/genetics.116.190496","volume":"204","author":"M Azim Ansari","year":"2016","unstructured":"Azim Ansari, M. & Didelot, X. Bayesian inference of the evolution of a phenotype distribution on a phylogenetic tree. Genetics 204, 89\u201398 (2016).","journal-title":"Genetics"},{"key":"25649_CR24","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1053\/j.gastro.2016.07.013","volume":"151","author":"S Ramirez","year":"2016","unstructured":"Ramirez, S., Mikkelsen, L. S., Gottwein, J. M. & Bukh, J. Robust HCV genotype 3a infectious cell culture system permits identification of escape variants with resistance to sofosbuvir. Gastroenterology 151, 973\u2013985.e2 (2016).","journal-title":"Gastroenterology"},{"key":"25649_CR25","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1136\/gutjnl-2014-308724","volume":"65","author":"A von Delft","year":"2016","unstructured":"von Delft, A. et al. The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design. Gut 65, 112\u2013123 (2016).","journal-title":"Gut"},{"key":"25649_CR26","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1080\/10408363.2019.1637394","volume":"56","author":"L Cuypers","year":"2019","unstructured":"Cuypers, L. et al. Next-generation sequencing for the clinical management of hepatitis C virus infections: Does one test fits all purposes? Crit. Rev. Clin. Lab. Sci. 56, 420\u2013434 (2019).","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"25649_CR27","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/hep.27375","volume":"61","author":"EF Donaldson","year":"2015","unstructured":"Donaldson, E. F., Harrington, P. R., O\u2019Rear, J. J., Naeger, L. K. & O\u2019Rear, J. J. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for Sofosbuvir. Hepatology 61, 56\u201365 (2015).","journal-title":"Hepatology"},{"key":"25649_CR28","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.jhep.2016.11.022","volume":"66","author":"D Wyles","year":"2017","unstructured":"Wyles, D. et al. Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir\/sofosbuvir. J. Hepatol. 66, 703\u2013710 (2017).","journal-title":"J. Hepatol."},{"key":"25649_CR29","unstructured":"Chen, Q. et al. Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. Antiviral Res. 174, 104694 (2020)."},{"key":"25649_CR30","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/liv.13327","volume":"37","author":"VC di Maio","year":"2017","unstructured":"di Maio, V. C. et al. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. Liver Int. 37, 514\u2013528 (2017).","journal-title":"Liver Int."},{"key":"25649_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3851\/IMP2125","volume":"23","author":"E Thomas","year":"2012","unstructured":"Thomas, E., Ghany, M. G. & Liang, T. J. Review the application and mechanism of action of ribavirin in therapy of hepatitis C. Antivir. Chem. Chemother. 23, 1\u201312 (2012).","journal-title":"Antivir. Chem. Chemother."},{"key":"25649_CR32","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jhep.2013.11.003","volume":"60","author":"EASL Clinical Practice Guidelines.","year":"2014","unstructured":"EASL Clinical Practice Guidelines. Management of hepatitis C virus infection. J. Hepatol. 60, 392\u2013420 (2014).","journal-title":"J. Hepatol."},{"key":"25649_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-8-402","volume":"8","author":"DA Feigelstock","year":"2011","unstructured":"Feigelstock, D. A., Mihalik, K. B. & Feinstone, S. M. Selection of hepatitis C virus resistant to ribavirin. Virol. J. 8, 402 (2011).","journal-title":"Virol. J."},{"key":"25649_CR34","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1053\/j.gastro.2018.02.017","volume":"154","author":"LV Pham","year":"2018","unstructured":"Pham, L. V. et al. HCV genotype 6a escape from and resistance to velpatasvir, pibrentasvir, and sofosbuvir in robust infectious cell culture models. Gastroenterology 154, 2194\u20132208.e12 (2018).","journal-title":"Gastroenterology"},{"key":"25649_CR35","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/jvh.13430","volume":"28","author":"U Fahn\u00f8e","year":"2021","unstructured":"Fahn\u00f8e, U. et al. Global evolutionary analysis of chronic hepatitis C patients revealed significant effect of baseline viral resistance, including novel non\u2010target sites, for DAA\u2010based treatment and retreatment outcome. J. Viral Hepat. 28, 302\u2013316 (2021).","journal-title":"J. Viral Hepat."},{"key":"25649_CR36","doi-asserted-by":"publisher","first-page":"5342","DOI":"10.1073\/pnas.0810950106","volume":"106","author":"V Schregel","year":"2009","unstructured":"Schregel, V., Jacobi, S., Penin, F. & Tautz, N. Hepatitis C virus NS2 is a protease stimulated by cofactor domains in NS3. Proc. Natl. Acad. Sci. USA 106, 5342\u20135347 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"25649_CR37","doi-asserted-by":"publisher","first-page":"10583","DOI":"10.1073\/pnas.90.22.10583","volume":"90","author":"A Grakoui","year":"1993","unstructured":"Grakoui, A., McCourt, D. W., Wychowski, C., Feinstone, S. M. & Rice, C. M. A second hepatitis C virus-encoded proteinase. Proc. Natl. Acad. Sci. USA 90, 10583\u201310587 (1993).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"25649_CR38","doi-asserted-by":"publisher","first-page":"6519","DOI":"10.1128\/JVI.00224-14","volume":"88","author":"CM Lange","year":"2014","unstructured":"Lange, C. M. et al. Determinants for membrane association of the hepatitis C Virus NS2 protease domain. J. Virol. 88, 6519\u20136523 (2014).","journal-title":"J. Virol."},{"key":"25649_CR39","doi-asserted-by":"publisher","first-page":"4665","DOI":"10.1128\/jvi.67.8.4665-4675.1993","volume":"67","author":"M Hijikata","year":"1993","unstructured":"Hijikata, M. et al. Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus. J. Virol. 67, 4665\u20134675 (1993).","journal-title":"J. Virol."},{"key":"25649_CR40","doi-asserted-by":"crossref","unstructured":"Popescu, C. I. et al. NS2 protein of hepatitis C virus interacts with structural and non-structural proteins towards virus assembly. PLoS Pathog. 7, e1001278 (2011).","DOI":"10.1371\/journal.ppat.1001278"},{"key":"25649_CR41","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/j.1365-2893.2011.01451.x","volume":"18","author":"K Morikawa","year":"2011","unstructured":"Morikawa, K. et al. Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus. J. Viral Hepat. 18, 305\u2013315 (2011).","journal-title":"J. Viral Hepat."},{"key":"25649_CR42","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1038\/nature04975","volume":"442","author":"IC Lorenz","year":"2006","unstructured":"Lorenz, I. C., Marcotrigiano, J., Dentzer, T. G. & Rice, C. M. Structure of the catalytic domain of the hepatitis C virus NS2-3 protease. Nature 442, 831\u2013835 (2006).","journal-title":"Nature"},{"key":"25649_CR43","unstructured":"Prongay, A. J. et al. Discovery of the HCV NS3\/4A protease inhibitor (1R,5S)-N-[3-amino-1- (cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino] carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0] hexan-2(S)-carboxamide (Sch 503034) II. J. Med. Chem. 50, 2310\u20132318 (2007)."},{"key":"25649_CR44","doi-asserted-by":"publisher","first-page":"8987","DOI":"10.1128\/JVI.00004-12","volume":"86","author":"J Jiang","year":"2012","unstructured":"Jiang, J. & Luo, G. Cell culture-adaptive mutations promote viral protein-protein interactions and morphogenesis of infectious hepatitis C virus. J. Virol. 86, 8987\u20138997 (2012).","journal-title":"J. Virol."},{"key":"25649_CR45","unstructured":"ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice E6(R1). (ICH Harmonised Tripartite Guideline, 1996)."},{"key":"25649_CR46","unstructured":"McLauchlan, J. et al. Cohort profile: The hepatitis C virus (HCV) research UK clinical database and biobank. Int. J. Epidemiol. 46, 1391\u20131391h (2017)."},{"key":"25649_CR47","doi-asserted-by":"crossref","unstructured":"Batty, E. M. et al. A modified RNA-seq approach for whole genome sequencing of RNA viruses from faecal and blood samples. PLoS ONE 8, e66129 (2013).","DOI":"10.1371\/journal.pone.0066129"},{"key":"25649_CR48","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.12688\/f1000research.7111.1","volume":"4","author":"D Bonsall","year":"2015","unstructured":"Bonsall, D. et al. ve-SEQ: Robust, unbiased enrichment for streamlined detection and whole-genome sequencing of HCV and other highly diverse pathogens. F1000Res 4, 1062 (2015).","journal-title":"F1000Res"},{"key":"25649_CR49","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1093\/bioinformatics\/btu033","volume":"30","author":"A Stamatakis","year":"2014","unstructured":"Stamatakis, A. RAxML version 8: A tool for phylogenetic analysis and post-analysis of large phylogenies. Bioinformatics 30, 1312\u20131313 (2014).","journal-title":"Bioinformatics"},{"key":"25649_CR50","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1126\/science.1114016","volume":"309","author":"BD Lindenbach","year":"2005","unstructured":"Lindenbach, B. D. et al. Complete replication of hepatitis C virus in cell culture. Science (N. Y., N. Y.) 309, 623\u2013626 (2005).","journal-title":"Science (N. Y., N. Y.)"},{"key":"25649_CR51","doi-asserted-by":"crossref","unstructured":"Fahn\u00f8e, U. & Bukh, J. In Methods in Molecular Biology. (ed. Law, M.) Vol. 1911 85\u201391 (Humana Press Inc., 2019).","DOI":"10.1007\/978-1-4939-8976-8_5"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-25649-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-25649-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-25649-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T11:21:16Z","timestamp":1669980076000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-25649-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,20]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["25649"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-25649-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.05.05.077230","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,20]]},"assertion":[{"value":"4 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.R.F.: Grants Consulting and Speaker\/Advisory Board: AbbVie, Alcura, Bristol-Myers Squibb, Gilead, Janssen, GlaxoSmithKline, Merck, Roche, Springbank, Idenix, Tekmira, Novartis. W.L.I.: Grants, Consulting and Advisory\/ Speaker Board: Roche, Janssen Cilag, Gilead Sciences, Novartis, GlaxoSmithKline, Pfizer, Abbvie and Bristol-Myers Squibb. All other D.A.S., C.F., A.M., R.B., N.C., J.F., J.M., P.S., V.P., S.R., J.B., E.B., M.A.A. authors have no competing interests to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6105"}}